Laboratory Report - The Methodist Hospital

Summer 2012
The
Laboratory Report
A Publication of the Department of Pathology and Genomic Medicine
Dr. Geoffrey Land Receives Celebration of Life Award
D
r. Geoffrey Land was the recipient
of the Celebration of Life
Award at the Methodist J.C.
Walter Jr. Transplant Center’s annual
Celebration of Life event in Crain Garden
on April 12th . Dr. A. Osama Gaber, medical
director of transplantation for the
Center, presented Dr. Land with the
award in recognition of his leadership in
the transplant program and for being a
vital member of the transplant team.
‚Geoff is essential to the success of our
ever-growing Center,‛ said Dr. Gaber.
‚He and his staff in the Histocompatibility
and Transplant Immunology Laboratory
impart a fundamental service that
allows us to provide excellent care to our
patients. Transplant surgery wouldn’t
Dr. Land with the Celebration of Life Award.
CAP ‘12 THE Pathologists’ Meeting:
The annual meeting of the College of
American Pathologists will be held from
September 9-12, 2012 at the Manchester
Grand Hyatt in San Diego, California. Dr.
Philip Cagle will moderate a Scientific
Plenary Session and Drs. Geoffrey Land
and Randall Olsen will present a short
course. In addition, 14 Department trainees
will present posters or abstracts. Registration
is still open at cap.org/
annual_meeting/2012.
34th Conference on Pediatric Disease Young Pathologists’ Section Retreat
July 30-August 2, 2012 August 18-19, 2012
Viceroy Snowmass Hotel Hyatt Regency Hill Country
Snowmass Village, Colorado San Antonio, Texas
For more information on these upcoming events for the Texas Society of Pathology,
visit texpath.org.
be possible without them.‛
Dr. Land is the medical director of Histocompatibility
and Transplant
Immunology (HLA) in the Department
of Pathology and Genomic Medicine.
The HLA Laboratory provides tissue
typing, cross-matching, and antibody
identification testing services for transplant
patients in The Methodist Hospital
System and at institutions served by The
Methodist Hospital System Reference
Laboratory.
For more information on Dr. Land, visit
methodisthealth.com/Land. For more information
on the Methodist J.C. Walter Jr.
Transplant Center, visit methodisthealth.com/transplantcenter.
�
2
3
4
5
6
7
8
Table of Contents
Breakthroughs in Molecular
Testing of Lung Cancer
Drs. Abdus Saleem and Donald
Weilbaecher Retire After Decades
of Service
Department Ranks Among Best in
World for Abstract Presentations
New Diagnostic Test Offerings
In Focus: The HLA Team
Lab Stats: Methodist Sugar Land
Hospital
Department Faculty Receive
Teaching Awards
New Trainees Start on July 1st
Methodist Laboratory Science
Students Win Bowl Competition
Summer Students Start on
June 4th
Trainee Spotlight

The
LABORATORY REPORT
Breakthroughs in Molecular Testing of Lung Cancer
L
ung cancer remains the leading
cause of cancer deaths worldwide,
but recent advances in diagnosis
and treatment will likely improve
these traditionally grim statistics.
Genomic data and radiological studies
continue to contribute novel information
on disease histology and pathogenesis,
allowing for the development and validation
of new, targeted molecular therapies
and the establishment of clearer correlations
between specific types of lung cancer
and responses to specific therapies.
‚Genomic sequencing provides us with
molecular biomarkers, usually oncogene
mutations, that can have significant predictive
value,‛ said Dr. Philip Cagle,
medical director of pulmonary pathology
for the Department. ‚Identifying these
markers in patient samples allows pathologists
to advise treating physicians
on the selection of therapies that are
Drs. Abdus Saleem and Donald Weilbaecher Retire After Decades of Service
D r.
Abdus
Saleem, codirector
of the
Coagulation Laboratory
and associate medical
director of hematopathology
for the Department,
and Dr. Donald Weilbaecher,
medical director
of autopsy pathology for
the Department, have
retired after a combined
67 years of dedicated
service to The Methodist Hospital
System.
‚Abdus is the embodiment of collegiality,
and it has been an honor to work with
him,‛ said Dr. James Musser, chair of the
Department. ‚He is a tremendous physician
and has been an important mentor in
our training programs. He will be missed,
but we wish him well in this next chapter
of his life.‛
more ‘personalized’
to specific targets in
the patients’ lung
cancer.‛
Two predictive biomarkers
for nonsmall-cell
lung cancer
(epidermal growth
factor receptor [EGFR] and anaplastic
lymphoma kinase [ALK]) have been clinically
validated, and tests for them are
now available at Methodist. Approximately
12 other biomarkers are in various
stages of investigation.
Dr. Cagle will moderate a scientific plenary
session on molecular testing of lung
cancer at the annual meeting of the College
of American Pathologists on September
9 th in San Diego. The new testing
guidelines for predictive biomarkers in
lung cancer are expected to be unveiled
at that meeting. These guidelines are
From left, Drs. Ethan Natelson, Abdus Saleem, James Musser, and James Davis
at a retirement reception on June 22 nd .
Dr. Saleem joined the medical staff at
Methodist in July of 1976 when he was
recruited from the Pennsylvania State
University College of Medicine in Hershey.
He has trained numerous local
hematopathologists over the years, including
Drs. Jacqueline O’Hare, Munir
Shahjahan, Choladda Curry, Randall
Olsen, Thu Ngo, and Christine Finch.
Spectra from an EGFR test.
established through a special committee
of the College of American Pathologists,
the Association for Molecular Pathology,
and the International Association for the
Study of Lung Cancer.
For more information on molecular
testing of lung cancer at Methodist,
please contact Dr. Randall Olsen in the
Molecular Diagnostics Laboratory at rjolsen@tmhs.org.
For more information on
Dr. Philip Cagle, visit methodisthealth.com/
Cagle. ���
The Department has established
the Dr. Abdus Saleem
Award. The award will be
given annually to a member
of the Department who
most epitomizes Dr.
Saleem’s outstanding professionalism
and commitment
to diversity.
Dr. Weilbaecher joined the
medical staff at Methodist in
1981.
‚During this time, he has
served as Director, Autopsy
Service, and has generously shared his
expertise with residents, medical students,
and other trainees,‛ said Dr.
Musser. Dr. Weilbaecher also has been
the Department’s leader in cardiovascular
pathology for much of his career. �
2

The
LABORATORY REPORT
Department Ranks Among Best in World for Abstract Presentations
T
he Methodist Department of
Pathology and Genomic Medicine
is in the top 20 of all institutions
worldwide for first-authored scientific
abstracts accepted for presentation
at the annual meeting of the
United States & Canadian Academy of
Pathology (USCAP). The Department
also ranked in the top 5% of all medical
institutions.
‚Our faculty and trainees are very
active academically,‛ said Dr. Alberto
Ayala, deputy chief of pathology for the
Department. ‚We expect to rank even
higher next year.‛
New Diagnostic Test Offerings:
Lung Cancer and Glial Tumor
Mutation Panels
The Molecular Diagnostics Laboratory of
The Methodist Hospital System has developed
new gene mutation panels for
lung and brain cancer. Somatic mutation
profiling determines whether patients
with non-small cell lung cancer or glial
brain tumors could benefit from a targeted
therapy. Non-small cell lung cancer
accounts for approximately 85-90% of
lung cancers, and includes squamous cell
carcinoma, adenocarcinoma, and large
cell carcinoma. Glial tumors are the most
common form of central nervous system
neoplasm, and include astrocytomas,
ependymomas, oligodendrogliomas, and
glioblastoma multiforme.
The new lung cancer panel tests for
mutations in the genes encoding
epidermal growth factor receptor
The ranking information was relayed to
Department leadership in June in a letter
from Dr. Bruce Smoller, Executive
Vice-President and Secretary-Treasurer
of USCAP. In 2012, there were over 3,000
scientific abstracts submitted to USCAP
from more than 400 medical school programs
and academic institutions (over
200 in the U.S. and Canada, and 200 from
the rest of the world).
For more information on the United
States & Canadian Academy of Pathology,
visit uscap.org. ��
Hundreds Attend Houston Lung Symposium
M
ore than 250 physicians and scientists attended the Houston Lung
Symposium on April 28th and 29th in The Methodist Hospital Research
Institute auditorium. The event was a collaboration between
the Houston Society of Clinical Pathologists and the Methodist Department
of Pathology and Genomic Medicine. The two-day symposium featured
renowned speakers from around the world.
(EGFR) and V-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog (KRAS).
The new glial tumor panel genotypes the
isocitrate dehydrogenase 1 (IDH1) and
IDH2 genes. IDH1 and IDH2 gene mutations
have also recently been associated
with acute myeloid leukemia, myelodysplastic
syndrome, and prostate cancer.
These assays are performed on the
Sequenom MassARRAY analyzer that
determines DNA sequences using PCR
and MALDI-TOF mass spectrometry.
EGFR, IDH1 and IDH2 testing
was previously performed at a reference
laboratory, and KRAS testing was previously
performed using pyrosequencing.
Validation studies for both panels
were supported, in part, through departmental
microgrants. The new molecular
diagnostic panels will be introduced inhouse
in August.
H&E stain of glioblastoma multiforme.
For more information on these panels
or other tests offered by the Molecular
Diagnostics Laboratory, please contact
Dr. Randall Olsen at 713-441-6802 or Ms.
Heather Hendrickson at 713-441-0504. �
3

The
LABORATORY REPORT
In Focus: The HLA Team
T he
Histocompatibility and Transplant
Immunology Laboratory
provides tissue typing, crossmatching,
and antibody identification
testing services for solid organ and bone
marrow transplant patients in The Methodist
Hospital System and at institutions
served by The Methodist Hospital System
Reference Laboratory.
The HLA laboratory also performs
microsatellite analysis for engraftment
monitoring, assays for immune cell function
monitoring, and human leukocyte
antigen (HLA) typing for disease associations
and pharmacogenomics.
Geoffrey A. Land, Ph.D., D(ABB)
Medical Director, Histocompatibility and
Transplant Immunology
Dr. Land received his Ph.D. in microbiology
from the Tulane University Medical
Center in New Orleans, Louisiana. He
then completed an NIH-sponsored research
fellowship in microbiology at the
Duke University Medical Center in Durham,
North Carolina.
Dr. Land has been in the fields of histocompatibility
and immunogenetics for
over 30 years, and has been actively involved
in quality assurance and the standardization
of histocompatibility laboratory
procedures and practices. He remains
an active laboratory inspector for
the College of American Pathologists and
the American Society for Histocompatibility
and Immunogenetics (ASHI). He is
the immediate past-president of ASHI
and is the president-elect of the Texas
Transplantation Society.
For more information on Dr. Land, visit
methodisthealth.com/Land.
Dr. Burns in the laboratory with HLA Medical Technologist
Andreea Acevedo.
The Department of
Pathology and Genomic
Medicine has
a team of three fulltime
faculty that
continues to grow to
keep pace with the
J.C. Walter Jr. Transplant
Center at
Methodist that it
serves, now the largest
transplant center
in Texas and the
Southwest.
Kevin Burns, M.D.
Co-Medical Director, Histocompatibility and
Transplant Immunology
Dr. Burns received his M.D. degree in
2006 from The University of Texas Health
Science Center at San Antonio. He completed
his clinical pathology residency in
2009, his transfusion medicine/blood
banking fellowship in 2010, and his HLA
fellowship in June of this year, all here at
Methodist. Dr. Burns joined the Department
as faculty in July of this year and
became co-director of the Histocompatibility
and Transplant Immunology Laboratory.
Dr. Burns is board certified in both
clinical pathology and blood banking/
transfusion medicine.
For more information on Dr. Burns,
visit methodisthealth.com/Burns.
The HLA team: from left, Drs. Geoffrey Land, Kevin Burns, and
Smaroula Dilioglou.
Smaroula Dilioglou, Ph.D., D(ABHI)
Associate Medical Director, Histocompatibility
and Transplant Immunology
Dr. Dilioglou received her Ph.D. in immunology
from the University of Mississippi
Medical Center in Jackson, Mississippi.
She then completed her postdoctoral
training at the St. Jude’s Children’s
Research Hospital in Memphis, Tennessee.
In addition to providing clinical services,
Dr. Dilioglou is especially involved
in HLA education of residents and fellows.
For more information on Dr. Dilioglou,
visit methodisthealth.com/Dilioglou.
For more information on the Histocompatibility
and Transplant Immunology
Laboratory at Methodist, please contact
Dr. Geoffrey Land at gland@tmhs.org. �
Dr. Dilioglou mentoring trainee Dr. Susan Haley in the Flow
Cytometry Laboratory.
4

The
LABORATORY REPORT
Lab Stats: Methodist Sugar Land Hospital
Medical Director: Seema Mullick, M.D.
Dr. Mullick received her medical degree
from the Christian Medical College
in Ludhiana, India. She completed a pathology
residency program and a cytopathology
fellowship at the Baylor College
of Medicine in Houston, Texas, followed
by a surgical pathology fellowship at The
University of Texas M.D. Anderson Cancer
Center.
Faculty: Bisong Haupt, M.D.
Dr. Haupt received her M.D. degree
from the Southeast University School of
Medicine in Nanjing, China. She is a
graduate of the pathology training programs
at Methodist, and a general surgical
pathologist.
Ognjen Kosarac, M.D.
Dr. Kosarac received his medical degree
from the University of Sarajevo in
Bosnia and Herzegovina. Like Dr. Haupt,
he is also a graduate of the pathology
training programs at Methodist. He has
subspecialty certification in cytopathology.
Director: Donna Hermis, M.H.A.
Ms. Hermis received her Master of
Healthcare Administration from Texas
Woman’s University. In addition to being
the director of the laboratory at
Methodist Sugar Land Hospital, she is
“We have an incredible group here in
the Sugar Land laboratory. We all really
love what we do, and we love Fort Bend
County; it’s a great place to work and
serve our patients.”
Seema Mullick, M.D.
“Dr. Mullick is a remarkable medical
director. I have enjoyed working with her
and the rest of the faculty and staff here.”
Bisong Haupt, M.D.
“I was pleased to be able to remain at
Methodist after my training; it is an impressive
hospital system, and I enjoy
working at both the main hospital in the
Texas Medical Center and at Sugar
Land.”
Ognjen Kosarac, M.D.
also the hospital safety officer. “This is a busy laboratory, especially
Manager: Rosalie Thornblom
Ms. Thornblom received her Bachelor
of Science in Medical Technology from
the University of Mary Hardin-Baylor.
She has been with the Sugar Land laboratory
since 2004, and became the manager
in 2007.
Staff:
The laboratory currently employs 42
staff members that include shift coordinators,
technologists, histologists, processors,
and technicians. These employees
demonstrate their ICARE values every
day to ensure that the laboratory is efficient
and that the patients and medical
staff at Methodist Sugar Land Hospital
are well served by their efforts. �
with the recent growth at the hospital and
the expansion of the Breast Center. We
all work together to make accuracy and
safety our main priorities, and we do it
well.”
Donna Hermis, M.H.A.
“Getting tests completed right and
quickly is very important. It takes a good
team to do that, and that’s what we have
here.”
Jennifer Selvidge, MLT Specialist
“Our laboratory continues to evolve
and expand. Like the hospital and the
community it serves, it just keeps getting
better.”
Rosalie Thornblom
Pictures from top: Dr. Mullick at the microscope; Dr. Haupt at the chemistry analyzer; Dr. Kosarac in the Histology Laboratory; Ms. Hermis in her office; and Ms.
Thornblom (right) with MLT Specialist Jennifer Selvidge.
5

The
LABORATORY REPORT
T
wo faculty members in the Department
received teaching
awards from the Graduate Medical
Education (GME) Department. Dr. Jae
Ro, medical director of surgical pathology,
and Dr. Arthur Zieske, co-director
of hematopathology, received the GME
Faculty Teaching Award on July 2nd,
from Dr. Judy Paukert, the GME Designated
Institutional Official for The Methodist
Hospital.
‚The success of our many programs
relies heavily on the contributions of
T
he Department welcomed 4 new
residents and 12 new fellows on
July 2nd during a half-day trainee
orientation session led by Dr. Suzanne
Powell, vice-chair of education for the
Department. The session followed a fourday
orientation provided by the hospital’s
GME office. Dr. Powell and the education
manager and coordinators greeted
the incoming trainees and apprised them
of the various support services in the
Department, including the training program
coordinators, a poster printing service,
and the Office of Academic Development.
‚Our department is large and busy; we
service a multi-site hospital system as
well as our reference laboratory clients.
We want to make sure our new trainees
transition into their programs quickly
and relatively seamlessly,‛ said Dr. Powell.
‚We are preparing the next generation
of practicing pathologists and investigative
pathologists, and we want to
ensure they have an outstanding training
experience.‛
The Department currently has 40 existing
trainees, with 21 of them having completed
their residency or fellowship program
and graduated as of June 30th. With
the 16 new trainees, the Department will
have a total of 38 residents and fellows
for the academic year 2012-13. The Department
of Pathology and Genomic
Medicine has a residency program, a resident
research program, and 11 fellowship
programs – the most training programs
of any department at Methodist.
Department Faculty Receive Teaching Award
great teachers and mentors like
Dr. Ro and Dr. Zieske,‛ said Dr.
Paukert. ‚We truly appreciate
their efforts with our trainees.‛
The awards are given annually
for exemplary teaching and are
voted on by the residents in their
respective programs.
For more information on
Department training programs,
visit methodisthealth.com/
pathologytraining. ���
New Trainees Start on July 1 st
PGY1 Residents
Miguelina De la Garza, M.D.
Escuela de Medicina Ignacio A. Santos,
Monterrey, Mexico
Maren Y. Fuller, M.D.
The University of Texas Medical School,
Houston
Jordan A. Roberts, M.D.
Louisiana State University School of
Medicine, New Orleans
Eric Salazar, M.D., Ph.D.
Weill Cornell Medical College, New
York
Incoming Fellows
Blood Bank/Transfusion Medicine
Miho Teruya, M.D.
Internal Medicine
Baylor College of Medicine
Cytopathology
Lindsay Waters, M.D.
AP/CP Residency
The Methodist Hospital
Bryan Janssen, M.D.
AP/CP Residency
The Methodist Hospital
Hematopathology
Adeel Muhammad Raza, M.D.
AP/CP Residency
St. John Hospital and Medical Center,
Detroit
Ramesh Bhagat, M.D.
AP/CP Residency
The University of Texas Southwestern
Medical Center, Dallas
Jae Ro, M.D., Ph.D. Arthur Zieske, M.D.
Molecular Genetic Pathology
Elizabeth McQuitty, M.D.
AP/CP Residency
The Methodist Hospital
Neuropathology
Jo Elle Peterson, M.D.
AP/CP Residency
The Methodist Hospital
Surgical Pathology
Laura Kidd, M.D.
AP/CP Residency
The University of Texas Medical School,
Houston
Crystal Trujillo, M.D.
AP/CP Residency
The University of Texas Medical School,
Houston
Sadhna Dhingra, M.D.
AP/CP Residency
The University of Texas Medical School,
Houston
Cecilia Clement, M.D.
AP/CP Residency
The University of Texas Medical
Branch, Galveston
Andrea Haws, M.D.
AP/CP Residency
Baylor College of Medicine
For more information on Department
training programs, visit methodisthealth.com/pathologytraining.
��
6

The
LABORATORY REPORT
Methodist Laboratory Science Students Win Bowl Competition
T
he team of four students
currently enrolled
in The Methodist
Hospital Medical Laboratory
Science (MLS) Program
won first place at the Texas
Association for Clinical Laboratory
Science (TACLS) Student
Bowl competition on
March 29th as part of the
TACLS Annual Meeting in
Fort Worth, Texas. A Methodist
team has won the competition
12 times in the past 24 years.
‚Winning the TACLS Bowl is testament
to the strength of our program,‛
said Tatia Feltman, program director for
the Methodist MLS Program. ‚We are
always proud of our students, and especially
so for taking first prize at a state-
T
welve summer students recently
began their three-month program
in the laboratories of some
of the Department’s faculty.
‚We have several impressive research
programs in our Department,‛ said Dr.
Patricia Chevez-Barrios, founder and
director of the Research Institute Summer
Student Program and director of
the Ocular Pathology Research Laboratory.
‚Our faculty are particularly committed
to developing the next generation
of physician scientists, and the
Summer Student Program is a great
opportunity to do that.‛
First established in 2005, the Summer
Student Program matches students with
faculty mentors in Research Institute
laboratories from June to August (10
weeks) and centers on a single research
project. During this time, the students
also attend required weekly didactic
lectures given by the mentors and invited
speakers. Students present their
work at the end of the program at a
student retreat.
Center for Molecular and Translational
Human Infectious Diseases Research
Laboratory of Dr. Edward Graviss
Valerie Brooker – Texas Tech
Methodist MLS Program students from left: Xinh Nguyen,
Bianca Natividad, Margaret Renfro, and Morgan Kilty.
wide competition such as this.‛
The Methodist MLS Program is a
twelve-month professional course of
study that is fully accredited by the National
Accrediting Agency for Clinical
Summer Students Start on June 4 th
Laboratory of Dr. Wesley Long
Alan Hsieh, Rice University
Laboratory of Dr. James M. Musser
Meredith Harrell – Paul Foster School
of Medicine
Gabriela Hinojosa-Garza – Tecnolόgico
de Monterrey
Oanh Truong – Rice University
Erika Versalovic – Colorado College
Laboratory of Dr. Randall Olsen
Deborah Saddington – Southwestern
University
Laboratory of Dr. Paul Sumby
Michael Au – Southwestern University
Laboratory Sciences
(NAACLS). Upon successful
completion of the program,
students will qualify for the
examination and certification
by the Board of Certification
of the American Society of
Clinical Pathology (ASCP).
Many of the graduates of the
program go on to work at
Methodist in one of our many
pathology laboratories. The
Methodist MLS Program has
been in existence since 1947.
For more information on the Methodist
MLS Program, visit methodisthealth.com/mlsprogram.
��
Dr. Paul Sumby (right) with Summer Student Michael Au.
Ocular Pathology Laboratory
Director, Dr. Patricia Chevez-Barrios
Maria Ethel Aguirre-Flores –
Tecnolόgico de Monterrey
Aravindh Ganapathy – Texas A&M
University
Cancer Pathology Laboratory
Director, Dr. Youli Zu
Eduardo Camacho-Martinez –
Tecnolόgico de Monterrey
Lucia Wang – Washington
University, St. Louis
For more information on the
Research Institute Summer Student
Program, visit methodisthealth.com/
SummerStudentProgram.�
7

The
LABORATORY REPORT
Trainee Spotlight:
Byron Moore, M.D.
Surgical Pathology Fellow
D r.
Byron Moore, a surgical pathology fellow, is the recipient of the Graduate Medical
Education (GME) Resident Leadership Award for the 2011-2012 academic year.
Dr. Moore received the award specifically for his exemplary leadership and service
to GRE. This is a special award bestowed annually upon residents, as determined by
the GME Designated Institutional Official, who have shown great leadership and commitment
with their participation in extracurricular responsibilities in GME.
Dr. Moore received his medical degree from The University of Texas Southwestern Medical
School in Dallas and completed all of his postdoctoral training at Methodist, which included
an AP/CP residency and fellowships in blood banking/transfusion medicine and
surgical pathology.
RECENT PUBLICATIONS
Dr. Moore (right) receiving his award from
Dr. Judy Paukert, GME Designated Institutional
Official for The Methodist Hospital.
Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of Polymyxin B-induced Nephrotoxicity: Implications
for Dosing Regimen Design. Antimicrob Agents Chemother. 2012 Jun 11. [Epub ahead of print]
Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran
etexilate therapy. Am J Clin Pathol. 2012 Apr;137(4):572-4.
Bae YS, Ro JY, Shim HS, Hong SW, Yoon SO. Pulmonary sclerosing haemangioma with metastatic spread to stomach. Histopathology.
2012 Jun;60(7):1162-4.
Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012 May;136(5):504-9.
Crombet O, Lastrapes K, Zieske A, Morales-Arias J. Complete morphologic and molecular remission after introduction of dasatinib in
the treatment of a pediatric patient with T-cell acute lymphoblastic leukemia and ABL1 amplification. Pediatr Blood Cancer. 2012
Aug;59(2):333-4.
Devos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, Patel SJ. Donor-specific HLA-DQ antibodies may contribute to poor
graft outcome after renal transplantation. Kidney Int. 2012 May 23. [Epub ahead of print]
Fittipaldi N, Olsen RJ, Beres SB, Van Beneden C, Musser JM. Genomic analysis of emm59 group A Streptococcus invasive strains,
United States. Emerg Infect Dis. 2012 Apr;18(4):650-2.
Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Marchiò C,
Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JS. Molecular evidence in support of the neoplastic and
precursor nature of microglandular adenosis. Histopathology. 2012 May;60(6B):E115-30.
Gorman BK, Kosarac O, Chakraborty S, Schwartz MR, Mody DR. Comparison of breast carcinoma prognostic/predictive biomarkers
on cell blocks obtained by various methods: cellient, formalin and thrombin. Acta Cytol. 2012;56(3):289-96.
Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA,
Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger
G, Graziano P, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD, Funkhouser WK. Validation of Interobserver
Agreement in Lung Cancer Assessment Hematoxylin-Eosin Diagnostic Reproducibility for Non-Small Cell Lung Cancer-The 2004
World Health Organization Classification and Therapeutically Relevant Subsets. Arch Pathol Lab Med. 2012 May 14. [Epub ahead of
print]
Hu Y, Zhao Q, Graviss EA, Jiang W, Yuan Z, Xu B. Use of the T-SPOT.TB assay to screen latent tuberculosis infection among the TB
contacts in Shanghai, China. J Infect. 2012 Jul;65(1):39-48.
Jian PY, Godoy G, Coburn M, Lynch G, Ro JY, Zhai QJ, Nishino M, Lerner SP. Adenocarcinoma following urinary diversion. Can Urol
Assoc J. 2012 Apr;6(2):E77-80.
Continued page 9
8

The
LABORATORY REPORT
RECENT PUBLICATIONS continued
Ko K, Ro JY, Hong EK, Lee S. Micropapillary lung cancer with breast metastasis simulating primary breast cancer due to architectural
distortion on images. Korean J Radiol. 2012 Mar;13(2):249-53.
Kundu UR, Guo M, Landon G, Wu Y, Sneige N, Gong Y. Fine-needle aspiration cytology of sclerosing adenosis of the breast: a retrospective
review of cytologic features in conjunction with corresponding histologic features and radiologic findings. Am J Clin Pathol.
2012 Jul;138(1):96-102.
Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross
JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green
RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. Response to Weltman and Fleury Malheiros, re
Lassman et al. Neuro Oncol. 2012 Jun;14(6):677-678.
Lee H, Jung SY, Ro JY, Kwon Y, Sohn JH, Park IH, Lee KS, Lee S, Kim SW, Kang HS, Ko KL, Ro J. Metaplastic breast cancer: clinicopathological
features and its prognosis. J Clin Pathol. 2012 May;65(5):441-6.
Lee SY, Kim KR, Park JY, Ro JY. Wilms' Tumor with Long-delayed Recurrence: 25 Years after Initial Treatment. Korean J Urol. 2012
Apr;53(4):288-92.
Marconescu P, Graviss EA, Musher DM. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and
telavancin compared to that of vancomycin. Scand J Infect Dis. 2012 Jun 5. [Epub ahead of print]
McGowan P, Nelles N, Wimmer J, Williams D, Wen J, Li M, Ewton A, Curry C, Zu Y, Sheehan A, Chang CC. Differentiating between
Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application
of a multiparameter scoring system. Am J Clin Pathol. 2012 Apr;137(4):665-70.
McQuitty E, Ro JY, Truong LD, Shen SS, Zhai Q, Ayala AG. Lymphovascular invasion in micropapillary urothelial carcinoma: a
study of 22 cases. Arch Pathol Lab Med. 2012 Jun;136(6):635-9.
Ozcan A, Truong LD. PAX2 and PAX8 Expression in the Ovarian Surface Epithelium and Inclusion Cysts. Am J Surg Pathol. 2012 Mar
31. [Epub ahead of print]
Shen SS, Truong LD, Scarpelli M, Lopez-Beltran A. Role of immunohistochemistry in diagnosing renal neoplasms: when is it really
useful? Arch Pathol Lab Med. 2012 Apr;136(4):410-7.
Shinder R, Ramirez SA, Chévez-Barrios P, Gombos DS. Re: "retinoblastoma associated orbital cellulitis". Ophthal Plast Reconstr Surg.
2012 May;28(3):235-7.
Shu I, Devaraj S, Hanson SE, Little RR, Wang P. Comparison of hemoglobin A1c measurements of samples with elevated fetal hemoglobin
by three commercial assays. Clin Chim Acta. 2012 May 26. [Epub ahead of print]
Wadhwa L, Bond WS, Perlaky L, Overbeek PA, Hurwitz MY, Chévez-Barrios P, Hurwitz RL. Embryonic Retinal Tumors in SV40 T-
Ag Transgenic Mice Contain CD133+ Tumor-Initiating Cells. Invest Ophthalmol Vis Sci. 2012 Jun 8;53(7):3454-62.
Wimmer JL, Long SW, Cernoch P, Land GA, Davis JR, Musser JM, Olsen RJ. A Strategy for Rapid Identification and Antibiotic Susceptibility
Testing of Gram-Negative Bacteria Directly Recovered from Positive Blood Cultures using the Bruker MALDI Biotyper and
BD Phoenix. J Clin Microbiol. 2012 Apr 18. [Epub ahead of print]
Yaziji H, Eisen R, Wick M, Swanson P, Badve S, Cartun R, Haas T, Marolt M, Hicks D, Martin A, Barry T, Alsabeh R, Taylor J, Fulton
R, Goldsmith J, Shen S, Taylor C. Immunohistochemistry Cocktails Are Here to Stay: Center of Medicare and Medicaid Services
Should Revise Its New Reimbursement Policy. Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):331-333.
Zhou H, Schwartz MR, Coffey D, Smith D, Mody DR, Ge Y. Should LSIL-H be a distinct cytology category?: A study on the frequency
and distribution of 40 human papillomavirus genotypes in 808 women. Cancer Cytopathol. 2012 May 30. [Epub ahead of print] ��
The Laboratory Report
The Laboratory Report is a publication
of The Methodist Hospital System
Department of Pathology and
Genomic Medicine.
Editor-in-Chief
April A. Ewton, M.D.
Editorial Committee
Hazel L. Awalt, M.D.
Christopher Leveque, M.D.
Claudia P. Molina, M.D.
Seema Mullick, M.D.
Thu Ngo, M.D.
Steven Shen, M.D., Ph.D.
Paul Sumby, Ph.D.
Ping Wang, Ph.D.
Editorial Coordinator
Philip Randall
Department Chair
James M. Musser, M.D., Ph.D.
9
The Methodist Hospital
Clare Rose, M.B.A.
Manuel Hinojosa, M.H.A.